Acyclovir - a review of the preclinical and early clinical data of a new antiherpes drug.
A review of the literature on acyclovir (Zovirax), a new antiherpes drug, with particular activity against herpes simplex virus types I and II and also against varicella-zoster, Epstein-Barr, cytomegalo and herpes B viruses, is presented. The article deals with 'in vitro' and 'in vivo' efficacy in animals, animal toxicity, latency and resistance, the mechanism of action and early clinical experience.
D000212:Acyclovir; D000818:Animals; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D006147:Guanine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D006168:Guinea Pigs; D006561:Herpes Simplex / Q000188:drug therapy; D006564:Herpesviridae / Q000187:drug effects; D006566:Herpesviridae Infections / Q000188:drug therapy*; D014645:Herpesvirus 3, Human / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000187:drug effects; D006801:Humans; D007408:Intestinal Absorption; D007635:Keratitis, Dendritic / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects; D007700:Kinetics; D051379:Mice; D010766:Phosphorylation; D011817:Rabbits; D018139:Simplexvirus / Q000187:drug effects; D013997:Time Factors
D006147:Guanine; D000212:Acyclovir